Current Trends in Treating Cervical Cancer

Taiwan Health and National Health Insurance Annual Statistics Information Service, 28 April, 2004. Available at http://www.doh.gov.tw/statistic/index.htm Walboomers, 1999, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J Pathol, 189, 12, 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F Ostor, 1993, Studies on 200 cases of early squamous cell carcinoma of the cervix, Int J Gynecol Pathol, 12, 193, 10.1097/00004347-199307000-00001 Hacker, 2000, Chapter 9: Cervical cancer, 357 Yang, 1999, Modified radical hysterectomy for early Ib cervical cancer, Gynecol Oncol, 74, 241, 10.1006/gyno.1999.5434 Keys, 1999, Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma, N Engl J Med, 340, 1154, 10.1056/NEJM199904153401503 Morris, 1999, Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer, N Engl J Med, 340, 1137, 10.1056/NEJM199904153401501 Chen, 2006, Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications, Int J Radiat Oncol Biol Phys, 66, 1370, 10.1016/j.ijrobp.2006.07.004 Ikushima, 2006, Chemoradiation therapy for cervical cancer: toxicity of concurrent weekly cisplatin, Radiat Med, 24, 115, 10.1007/BF02493277 Einstein, 2007, Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer, Cancer, 109, 48, 10.1002/cncr.22369 Candelaria, 2006, Radiosensitizers in cervical cancer. Cisplatin and beyond, Radiat Oncol, 1, 15, 10.1186/1748-717X-1-15 Wydra, 2006, Sentinel node identification in cervical cancer patients undergoing transperitoneal radical hysterectomy: a study of 100 cases, Int J Gynecol Cancer, 16, 649, 10.1111/j.1525-1438.2006.00402.x Vrdoljak, 2006, Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix—final results of a prospective phase II-study, Gynecol Oncol, 103, 494, 10.1016/j.ygyno.2006.03.060 Kim, 1989, Two-year survival: preoperative adjuvant chemotherapy in the treatment of cervical cancer stages Ib and II with bulky tumors, Gynecol Oncol, 33, 225, 10.1016/0090-8258(89)90557-X Eddy, 1995, Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage Ib bulky cervical cancer: a gynecologic oncology group pilot study, Gynecol Oncol, 57, 412, 10.1006/gyno.1995.1164 Benedetti Panici, 1988, Neoadjuvant chemotherapy and radical surgery in locally advanced cervical carcinoma: a pilot study, Obstet Gynecol, 71, 344 Kumar, 1994, Randomized phase III study of neoadjuvant chemotherapy + radiotherapy vs. radiotherapy alone in locally advanced cervical cancer, Proc Am Soc Clin Oncol, 13, A819 Tierney, 2003, Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials, Eur J Cancer, 39, 2470, 10.1016/S0959-8049(03)00425-8 Sardi, 2005, Neoadjuvant chemotherapy in cervical cancer: a new trend, Curr Opin Obstet Gynecol, 17, 43, 10.1097/00001703-200502000-00008 Thigpen, 1981, Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group, Cancer, 48, 899, 10.1002/1097-0142(19810815)48:4<899::AID-CNCR2820480406>3.0.CO;2-6 Stehman, 1989, A phase II evaluation of mitolactol (NSC #104800) in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study, J Clin Oncol, 7, 1892, 10.1200/JCO.1989.7.12.1892 McGuire, 1996, Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study, J Clin Oncol, 14, 792, 10.1200/JCO.1996.14.3.792 Burnett, 2000, A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix, Gynecol Oncol, 76, 63, 10.1006/gyno.1999.5657 Omura, 1997, Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study, J Clin Oncol, 15, 165, 10.1200/JCO.1997.15.1.165 Moore, 2004, Phase III study of cisplatin with or without paclitaxel in Stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study, J Clin Oncol, 22, 3113, 10.1200/JCO.2004.04.170 Long, 2002, Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature, Am J Clin Oncol, 25, 547, 10.1097/00000421-200212000-00002 Long, 2005, Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix, J Clin Oncol, 23, 4626, 10.1200/JCO.2005.10.021 Ljubojevic, 2006, The human papillomavirus vaccines, Acta Dermatovenerol Croat, 14, 208 Mahdavi, 2005, Vaccines against human papillomavirus and cervical cancer: promises and challenges, Oncologist, 10, 528, 10.1634/theoncologist.10-7-528 Bourgault-Villada, 2007, Anti Human-Papillomavirus vaccines: concepts, aims and trials, Rev Med Interne, 28, 22, 10.1016/j.revmed.2006.09.025 Birle, 2006, Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts, Mol Cancer Ther, 5, 2494, 10.1158/1535-7163.MCT-05-0504